IRF4 and Miyoshi myopathy: Lenalidomide stabilizes CRBN and facilitates IRF4 degradation in MM cells and the combination of panobinostat and lenalidomide was found to exert synergistic effects partly due to the simultaneous suppression of HO-1, IRF4, and c-Myc.